Beyondspring INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ

12 Nov 2025

BYSI

10-Q: BeyondSpring Narrows 9M Loss, Boosts Cash Amid SEED Divestiture

BeyondSpring Inc. reported a significantly reduced consolidated net loss for the first nine months of 2025, driven by a gain from the partial sale of its SEED Therapeutics subsidiary, while advancing its lead asset Plinabulin.

NASDAQ

13 Aug 2025

BYSI

Beyondspring INC

10-Q: BeyondSpring Boosts Cash, Focuses on Plinabulin Pipeline

BeyondSpring Inc. reports improved financial health and strategic focus on its lead asset Plinabulin after divesting a portion of its SEED Therapeutics stake.

NASDAQ

12 May 2025

BYSI

Beyondspring INC

10-Q: BeyondSpring Inc. Reports Q1 2025 Results, Highlights SEED Therapeutics Divestiture

BeyondSpring Inc. reports a net income of $1.2 million for Q1 2025, driven by a gain from the sale of SEED Therapeutics shares, while continuing to advance its Plinabulin pipeline.